Arikayce
Drug
Insmed, Inc.
Total Payments
$23.0M
Transactions
76,160
Doctors
11,497
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.9M | 15,736 | 5,143 |
| 2023 | $7.8M | 16,460 | 4,545 |
| 2022 | $6.9M | 12,939 | 4,191 |
| 2021 | $2.4M | 11,998 | 3,837 |
| 2020 | $629,725 | 7,141 | 2,555 |
| 2019 | $2.4M | 11,886 | 3,802 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.6M | 8,200 | 76.5% |
| Consulting Fee | $1.5M | 833 | 6.4% |
| Food and Beverage | $1.4M | 59,151 | 6.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 616 | 5.5% |
| Grant | $495,566 | 19 | 2.2% |
| Travel and Lodging | $483,251 | 1,360 | 2.1% |
| Education | $216,548 | 5,921 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $93,090 | 60 | 0.4% |
Payments by Type
Research
$17.6M
8,200 transactions
General
$5.4M
67,960 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | Insmed, Inc. | $9.5M | 9 |
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) | Insmed, Inc. | $4.8M | 0 |
| ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | Insmed, Inc. | $1.0M | 0 |
| ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | Insmed, Inc. | $878,131 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | Insmed, Inc. | $649,851 | 1 |
| A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | Insmed, Inc. | $347,039 | 0 |
| An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | Insmed, Inc. | $267,005 | 0 |
Top Doctors Receiving Payments for Arikayce
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $18.2M | 8,155 |
| , M.D | Pulmonary Disease | Independence, OH | $199,463 | 444 |
| , MD | Pulmonary Disease | Tyler, TX | $182,458 | 173 |
| , D.O | Infectious Disease | Suwanee, GA | $147,577 | 325 |
| , MD.,FRCP., FCCP(C) | Pulmonary Disease | New Orleans, LA | $122,358 | 176 |
| , D.O | Infectious Disease | Portland, OR | $115,844 | 179 |
| , MD | Pulmonary Disease | Weston, FL | $114,207 | 166 |
| , M.D | Student in an Organized Health Care Education/Training Program | New Orleans, LA | $97,063 | 88 |
| , MD | Internal Medicine | Anderson, SC | $88,837 | 142 |
| , M.D | Internal Medicine | Tyler, TX | $81,948 | 164 |
| , MD | Pulmonary Disease | Loma Linda, CA | $81,575 | 99 |
| , MD | Pulmonary Disease | San Diego, CA | $80,175 | 93 |
| , MD | Critical Care Medicine | Denver, CO | $64,873 | 91 |
| , MD | Pulmonary Disease | New York, NY | $59,492 | 183 |
| , MD | Internal Medicine | Tyler, TX | $54,015 | 51 |
| , MD | Critical Care Medicine | San Antonio, TX | $48,238 | 64 |
| , MD | Pulmonary Disease | Milwaukee, WI | $45,764 | 77 |
| , M.D | Pulmonary Disease | Flushing, NY | $43,589 | 110 |
| , M.D | Internal Medicine | Tampa, FL | $41,768 | 82 |
| , MD | Infectious Disease | Portland, OR | $39,731 | 47 |
| , MD | Infectious Disease | Denver, CO | $38,157 | 48 |
| , DO | Infectious Disease | Kingston, NY | $36,211 | 68 |
| , M.D | Pulmonary Disease | Bayside, NY | $35,330 | 71 |
| , M.D | Infectious Disease | Derry, NH | $34,896 | 52 |
| , M.D | Sleep Medicine | Burlingame, CA | $34,852 | 86 |
Ad
Manufacturing Companies
- Insmed, Inc. $23.0M
Product Information
- Type Drug
- Total Payments $23.0M
- Total Doctors 11,497
- Transactions 76,160
About Arikayce
Arikayce is a drug associated with $23.0M in payments to 11,497 healthcare providers, recorded across 76,160 transactions in the CMS Open Payments database. The primary manufacturer is Insmed, Inc..
Payment data is available from 2019 to 2024. In 2024, $2.9M was paid across 15,736 transactions to 5,143 doctors.
The most common payment nature for Arikayce is "Unspecified" ($17.6M, 76.5% of total).
Arikayce is associated with 7 research studies, including "A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact" ($9.5M).